Long-term intraocular pressure changes after intravitreal injection of bevacizumab

Baek, Sung Uk; Park, In Won; Suh, Wool

doi:10.3109/15569527.2015.1124886

Cited by 35 publications

(27 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There were five RCTs1920212223 and 17 non-RCT studies1415161724252627282930313233343536. The latter group included 11 retrospective case series1417242526272829303132, two prospective studies3334, and four post hoc analyses15163536. Follow-up in the included articles ranged from 2.2627 to 6031 months.…”

Section: Resultsmentioning

confidence: 99%

“…Eleven retrospective1417242526272829303132 and two prospective3334 studies, which reported the case numbers and incidence rates of SE-IOP among the 5062 subjects, were analyzed. Prevalence of SE-IOP varied from 1.6% (5 of 302 cases) to 11% (22 of 201 case), with a pooled prevalence (Fig.…”

Section: Resultsmentioning

confidence: 99%

“…S1). Among the 2366 subjects who received intravitreal injection of bevacizumab in eleven studies1417242526282930313233, 104 developed SE-IOP, with a pooled prevalence of 3.8% (CI 2.3–5.4) in a random effects model, with significant heterogeneity ( I 2 = 70.1%) (Fig. S2).…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Sustained Elevation of Intraocular Pressure Associated with Intravitreal Administration of Anti-vascular Endothelial Growth Factor: A Systematic Review and Meta-Analysis

Zhou

Xia

et al. 2016

Sci Rep

View full text Add to dashboard Cite

This study aimed to assess whether repetitive intravitreal injections (IVI) of anti-vascular endothelial growth factor (anti-VEGF) cause sustained elevation of intraocular pressure (SE-IOP). We conducted a systematic review and meta-analysis based on five randomized controlled trials (RCTs) assessing 1428 subjects and 17 non-RCTs evaluating 8358 cases. In the RCTs, an increased risk of SE-IOP was found in the anti-VEGF group (summary risk ratio [RR] = 3.00, 95% confidence interval [CI]: 1.63–5.53) compared with the sham injection or laser group. The increased risk of SE-IOP was correlated with follow-up duration (RR = 2.14, 95% CI 0.69–6.57 at 6 months; RR = 3.15, 95% CI 0.99–10.09 at 12 months; RR = 3.48, 95% CI 1.38–8.78 at 23 months). The risk of SE-IOP after non-exclusion of pre-existing glaucoma patients (RR = 3.48, 95% CI 1.38–8.78) was higher than that obtained after excluding pre-existing glaucoma patients (RR = 2.6, 95% CI 1.16–5.81). In non-RCTs, the pooled prevalence of SE-IOP was 4.7% (95% CI 3.7–5.8) regardless of diagnosis criteria. In conclusion, repeated intravitreal injections of anti-VEGF agents cause a 2-fold elevation in SE-IOP risk.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Sustained Elevation of Intraocular Pressure Associated with Intravitreal Administration of Anti-vascular Endothelial Growth Factor: A Systematic Review and Meta-Analysis

Zhou

Xia

et al. 2016

Sci Rep

View full text Add to dashboard Cite

show abstract

“…17 Over the years, several other studies have been published with varying numbers of patients reporting the prevalence of longterm IOP increase after treatment with bevacizumab, ranibizumab or aflibercept injections. [17][18][19][20][21][22][23][24][25][26][27][28][29][30] One of the studies with the largest number of patients (retrospective analysis of VIEW 1 and 2 study data from a total of 2457 patients) showed a significantly higher IOP increase in eyes after ranibizumab treatment than in patients after aflibercept treatment. 31 In 2016 Zhou et al conducted a meta-analysis of 5 randomized controlled trials (RCT) in 1428 patients and 8358 patients from 17 non-RCTs.…”

Section: Possible Side Effects From Intravitreal Injections Elevated mentioning

confidence: 99%

<p>Issues with Intravitreal Administration of Anti-VEGF Drugs</p>

Schargus¹,

Фрингс²

2020

OPTH

View full text Add to dashboard Cite

Purpose: To provide an update of summary of risk factors and side effects of long-term use and contamination of intravitreal anti-VEGF injections. Methods: We reviewed relevant publications of the topic of contamination of anti-VEGF injections and long-term side effects due to this reason. Results: Due to the long-term use of anti-VEGF drugs and the higher number of injections worldwide, various studies have shown side effects in recent years, ranging from increased intraocular pressure to visual disturbing silicone oil vesicles in the vitreous cavity. Several studies have demonstrated that both the drug and the processing, storage, environmental factors and the material and design of the syringes have a decisive influence on these side effects.Conclusion: The risks of deposits from syringes in the eye can be significantly reduced by various optimizations in transport, storage and syringe and cannula selection.

show abstract

“…Kurzfristige Druckanstiege sind auch hier durch die reine Volumenzunahme unmittelbar post injectionem erklärt. Darüber hinaus gab es in der jüngeren Vergangenheit einige Publikationen, die über eine erhöhte Prävalenz andauernder Druckanstiege (Häufigkeit 6-11 %) nach multiplen Anti-VEGF-Injektionen berichteten [15][16][17]. Eine Reihe möglicher Risikofaktoren für dieses Phänomen wurden benannt: Zahl der Injektionen, Abstand zwischen den Injektionen unter 8 Wochen, bekanntes Glaukom, retinaler Venenastverschluss.…”

Section: Augendrucksteigerung Nach Intravitrealer Okulärer Medikamentunclassified

Der Einfluss von Medikamenten auf das Glaukom und den Augeninnendruck

Schlote¹

2017

Klin Monatsbl Augenheilkd

View full text Add to dashboard Cite

Systemic drugs may have unfavourable effects on intraocular pressure, glaucoma and the efficacy of glaucoma drugs. The article provides a review of the literature from PubMed and clinical experience. Topical and systemic corticosteroids induce complex changes inside the trabecular meshwork. New genetic results improve the understanding of pathogenetic processes, although many questions are still open. Arterial hypertension and antihypertonic drugs may influence the risk of glaucoma, intraocular pressure and ocular perfusion pressure. Intravitreal anti-VEGF therapy may be associated with the risk of sustained intraocular pressure elevation. Systemic drugs with parasympaticolytic activity (e.g. psychopharmaceuticals) are able to induce acute angle block glaucoma. New insights into the interactions between drugs (e.g. antihypertensives, corticosteroids) and glaucomatous optic neuropathy affect large patient groups and may improve understanding of the underlying pathogenetic processes in open angle glaucoma. There is a great need for further clinical and experimental research.

show abstract

Long-term intraocular pressure changes after intravitreal injection of bevacizumab

Abstract: Our results suggest that under long-term monitoring, with a treat-and-extended regimen, intravitreal bevacizumab injections were associated with sustained IOP elevation. In particular, multiple intravitreal injections could be associated with sustained IOP elevation.

Cited by 35 publications

References 30 publications

Sustained Elevation of Intraocular Pressure Associated with Intravitreal Administration of Anti-vascular Endothelial Growth Factor: A Systematic Review and Meta-Analysis

Sustained Elevation of Intraocular Pressure Associated with Intravitreal Administration of Anti-vascular Endothelial Growth Factor: A Systematic Review and Meta-Analysis

<p>Issues with Intravitreal Administration of Anti-VEGF Drugs</p>

Der Einfluss von Medikamenten auf das Glaukom und den Augeninnendruck

Contact Info

Product

Resources

About